Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

46 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. Razavi H, et al. Among authors: Ferreira PR. J Viral Hepat. 2014 May;21 Suppl 1:34-59. doi: 10.1111/jvh.12248. J Viral Hepat. 2014. PMID: 24713005
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
Benzaken AS, Girade R, Catapan E, Pereira GFM, Almeida EC, Vivaldini S, Fernandes N, Razavi H, Schmelzer J, Ferraz ML, Ferreira PRA, Pessoa MG, Martinelli A, Souto FJD, Walsh N, Mendes-Correa MC. Benzaken AS, et al. Among authors: Ferreira PRA. Braz J Infect Dis. 2019 May-Jun;23(3):182-190. doi: 10.1016/j.bjid.2019.04.010. Epub 2019 May 27. Braz J Infect Dis. 2019. PMID: 31145876 Free article.
HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE.
Castelo A, Mello CEB, Teixeira R, Madruga JVR, Reuter T, Pereira LMMB, Silva GF, Álvares-DA-Silva MR, Zambrini H, Ferreira PRA. Castelo A, et al. Among authors: Ferreira PRA. Arq Gastroenterol. 2018 Oct-Dec;55(4):329-337. doi: 10.1590/S0004-2803.201800000-74. Arq Gastroenterol. 2018. PMID: 30785514 Free article.
Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus.
Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Grando AV, et al. Among authors: Ferreira PRA. Rev Inst Med Trop Sao Paulo. 2017 Nov 6;59:e67. doi: 10.1590/S1678-9946201759067. Rev Inst Med Trop Sao Paulo. 2017. PMID: 29116287 Free PMC article. Clinical Trial.
SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interruption due to SAE (PR 0.36; 95% CI 0.20-0.68; p=0.001). Early treatment interruption due to SAE was associated with age (PR 1.06; 95% CI 1.02-1.10; p<0.001) and occurrence of liver cirrhosis (PR 2.06; 95% CI 1.11-3.83; p=0.022). ...
SVR was negatively associated with the use of Peg-IFN alpha 2b (PR 0.75; 95% CI 0.58-0.99; p=0.045) and to early treatment interrupti …
Disease burden of chronic hepatitis C in Brazil.
Ferreira PR, Brandão-Mello CE, Estes C, Gonçales Júnior FL, Coelho HS, Razavi H, Cheinquer H, Wolff FH, Ferraz ML, Pessoa MG, Mendes-Correa MC. Ferreira PR, et al. Braz J Infect Dis. 2015 Jul-Aug;19(4):363-8. doi: 10.1016/j.bjid.2015.04.004. Epub 2015 Jun 4. Braz J Infect Dis. 2015. PMID: 26051505
Strategies to manage hepatitis C virus (HCV) disease burden.
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E. Wedemeyer H, et al. Among authors: Ferreira PR. J Viral Hepat. 2014 May;21 Suppl 1:60-89. doi: 10.1111/jvh.12249. J Viral Hepat. 2014. PMID: 24713006
Historical epidemiology of hepatitis C virus (HCV) in selected countries.
Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL Jr, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ. Bruggmann P, et al. Among authors: Ferreira PR. J Viral Hepat. 2014 May;21 Suppl 1:5-33. doi: 10.1111/jvh.12247. J Viral Hepat. 2014. PMID: 24713004 Review.
The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.
Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC. Ferreira PR, et al. Braz J Infect Dis. 2015 Jan-Feb;19(1):15-22. doi: 10.1016/j.bjid.2014.08.002. Epub 2014 Sep 1. Braz J Infect Dis. 2015. PMID: 25181403 Clinical Trial.
Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.
Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ; Brazilian HCV-Related Advanced Fibrosis Study Group. Silva GF, et al. Among authors: Ferreira PR. Braz J Infect Dis. 2014 Jan-Feb;18(1):48-52. doi: 10.1016/j.bjid.2013.05.007. Epub 2013 Sep 20. Braz J Infect Dis. 2014. PMID: 24055310 Clinical Trial.
46 results
Jump to page
Feedback